KraneShares Electric Vehicles and Future Mobility Index ETF (ARCA: KARS)

Dernières nouvelles pour KraneShares Electric Vehicles and Future Mobility Index ETF (ARCA:KARS)

Consumer Cyclical

Basic Materials

Other

Industrials

Technology

Consumer Defensive

Real Estate

Energy

The fund will invest at least 80% of its total assets in components of the index, depositary receipts, including ADRs, representing such components, and securities underlying depositary receipts in the index. The index is designed to track the equity market performance of companies engaged in the production of electric vehicles or their components or in other initiatives that may change the future of mobility, as determined by index provider. The fund is non-diversified.

Tesla, Inc.

Byd Co Ltd

Li Auto Inc-Class A

Panasonic Corp

Rivian Automotive

Samsung Sdi Co Ltd

Albemarle Corp.

KraneShares Electric Vehicles and Future Mobility Index ETF

KARSAN OTOMOTIV SNAYII by KARSAN OTOMOTIV SANAYII VE TICARET AS

Karsan Otomotiv Sanayii Ve Ticaret AS

News

Trading Ideas

Market Vectors ETF Trust Market Vectors Gold Miners

MSTR

Rydex ETF Trust Rydex S&P Equal Weight ETF

Elliott Investment Management 13F Shows Exited Position In Marathon Petroleum, Previously Holding 7,365,000 Shares; Ishares Biotechnology ETF Put Position, Previously Holding 2,800,000 Shares; Invesco S&P 500 Equal Weight ETF Put Position, Previously Holding 1,925,000 Shares; Vaneck Gold Miners ETF Put Position, Previously Holding 5,000,000 Shares; BHP Group Ltd Call Position, Previously Holding 2,500,000 Shares; MicroStrategy Convertible Note, Previously Holding $27.5 Million In Principal

Cue Biopharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CUE#NASDAQ">CUE</a>) reported quarterly losses of $(0.17) per share which beat the analyst consensus estimate of $(0.19) by 10.53 percent. The company reported quarterly sales of $3.336 million which beat the analyst consensus estimate of $1.520 million by 119.55 percent. This is a 58.86 percent increase over sales of $2.100 million the same period last year.

Earnings

Earnings Beats

Cue Biopharma Q3 2024 GAAP EPS $(0.17) Beats $(0.19) Estimate, Sales $3.336M Beat $1.520M Estimate

WIIM

HALO

Evotec shares are trading higher after the company announced it received a proposal to be acquired by Halozyme for approximately $2.1 billion.

HOOKIPA Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HOOK#NASDAQ">HOOK</a>) reported quarterly losses of $(1.10) per share which beat the analyst consensus estimate of $(1.28) by 14.06 percent. The company reported quarterly sales of $4.703 million which missed the analyst consensus estimate of $6.250 million by 24.75 percent. This is a 31.51 percent decrease over sales of $6.867 million the same period last year.

Earnings Misses

HOOK

HOOKIPA Pharma Q3 2024 GAAP EPS $(1.10) Beats $(1.28) Estimate, Sales $4.703M Miss $6.250M Estimate

General

Kezar Life Sciences Received A Letter From The Listing Qualifications Staff Of The Nasdaq Notifying The Company That It Has Regained Compliance With Nasdaq Listing Rule 5550(A)(2)

Biotech

Events

SLNO

Soleno Therapeutics Announces Presentation Featuring Diazoxide Choline Extended-Release Tablets In Prader-Willi Syndrome At ESPE 2024

SDRL

Elliott Investment Management 13F Shows Decreased Put Position In Vaneck Oil Services ETF From 1,450,000 To 1,260,000 Shares; Decreased Stake In NRG Energy By 7% From 10,359,000 To 9,668,000 Shares; Decreased Stake In Seadrill Ltd By 9% From 4,050,984 To 3,703,746 Shares; Decreased Stake In XME Put Position By 18% From 5,000,000 To 4,100,000 Shares; Decreased Stake In Ishares QQQ Trust Put Position By 92% From 5,910,000 Shares To 450,000 Shares

Oklo Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OKLO#NYSE">OKLO</a>) reported third-quarter financial results after the market close on Thursday. Here&#8217;s a rundown of the <a href="https://www.benzinga.com/pressreleases/24/11/b41988748/oklo-publishes-third-quarter-2024-financial-results-and-business-update">nuclear company&#8217;s report</a>.
Q3 Earnings: Oklo reported a third-quarter loss of eight cents per share, according to <a href="http://pro.benzinga.com">Benzinga Pro</a>. The Sam Altman-backed company noted it used $24.9 million of cash in operations year-to-date.
Oklo reported operating losses of $37.4 million since the start of the year. The company said it remains on track to meet its full-year operating loss forecast of $40 to $50 million.
Oklo ended the quarter with $288.5 million in cash, cash equivalents and marketable securities. 
&#8220;We are entering an era of unprecedented energy demand — rivaled perhaps only by initial conversion to electrification over a century ago. The world is now recognizing nuclear's role in powering that future,&#8221; said Jacob DeWitte, co-founder and CEO of Oklo.
&#8220;Momentum is building every week — regulators are modernizing, bipartisan support is growing and some of the most influential companies are investing heavily in the space.&#8221;
Don&#8217;t Miss: <a href="https://www.benzinga.com/top-stories/24/11/41915547/trumps-fossil-fuel-push-may-satisfy-ais-soaring-energy-demand-but-what-about-nuclear">Trump&#8217;s Fossil Fuel Push May Satisfy AI&#8217;s Soaring Energy Demand — But What About Nuclear?</a>
Oklo announced earlier this week that it&#8217;s partnering with two major data center providers to deliver up to 750 MW of power. The commitments bring Oklo's customer pipeline up to approximately 2,100 MW.
Oklo also said it plans to submit its combined license application to the U.S. Nuclear Regulatory Commission (NRC) during the first half of 2025.
&#8220;With a site permit and secured fuel, we believe we're poised to be a leader in deploying advanced nuclear by late 2027. As the world experiences an extraordinary transformation driven by AI, the future demands an equally bold solution for energy. We're proud to lead the way,&#8221; DeWitte said. 
Management will hold a call to discuss the quarter with investors and analysts at 4:30 p.m. ET.
OKLO Price Action: <a href="http://benzinga.com/quote/oklo" target="_blank" rel="noreferrer noopener">Oklo shares</a> were down 5.74% in after hours, trading at $22.51 at the time of publication, according to <a href="http://pro.benzinga.com/" target="_blank" rel="noreferrer noopener">Benzinga Pro</a>.
Photo: Courtesy of Oklo.

After-Hours Center

Movers

OKLO

Sam Altman-Backed Oklo Reports Q3 Earnings: 'Momentum Is Building Every Week'

TFFP

Trading Halt: Halt status updated at 4:40:00 PM ET: Quotation Resumption: News and Resumption Times

Flexible Solutions Intl (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/FSI#AMEX">FSI</a>) reported quarterly earnings of $0.05 per share which missed the analyst consensus estimate of $0.06 by 16.67 percent. This is a 183.33 percent increase over losses of $(0.06) per share from the same period last year. The company reported quarterly sales of $9.31 million which missed the analyst consensus estimate of $10.88 million by 14.38 percent. This is a 6.81 percent increase over sales of $8.72 million the same period last year.

Flexible Solutions Intl Q3 EPS $0.05 Misses $0.06 Estimate, Sales $9.31M Miss $10.88M Estimate

Federal Reserve Chair Jerome Powell indicated Thursday the remarkable strength of the U.S. economy is not sending any signals that policymakers &#8220;need to be in a <a href="https://www.benzinga.com/topic/interest-rates">hurry to lower rates.&#8221;</a>
Powell&#8217;s remarks came at an event organized by the Dallas Regional Chamber on Thursday, just a week after his press conference following the November Federal Reserve meeting.
&#8220;Inflation is running much closer to our 2% longer-run goal, but it is not there yet. We are committed to finishing the job,&#8221; Powell said. 
The Fed chair hinted that interest rates may be moving &#8220;to a more neutral setting,&#8221; but stressed that &#8220;the path for getting there is not preset.&#8221;
<h3 class="wp-block-heading">Powell Hints At Economic Strength, Warns About Risk Of Tariff Retaliations</h3>
Powell described the U.S. economy&#8217;s recent performance as &#8220;by far the best of any major economy in the world.&#8221; He attributed this strength in part to increased productivity.
&#8220;Productivity has grown faster over the past five years than its pace in the two decades before the pandemic, increasing the productive capacity of the economy and allowing rapid economic growth without overheating,&#8221; he said.
This resilience in the economy, according to Powell, gives the Federal Reserve the flexibility to &#8220;approach our decisions carefully,&#8221; though he underscored that the future path of interest rates would depend on how incoming data and economic forecasts evolve.
Powell expressed confidence that, with careful adjustments to the Fed's policy stance, the strength of both the economy and the labor market could be preserved, while inflation trends back down to the Fed&#8217;s 2% target.
Regarding the labor market, Powell downplayed the significance of the October jobs report, noting it was influenced by temporary factors such as hurricanes and labor strikes.
He also indicated no urgency to change Fed policy in response to potential shifts in fiscal policy under the new Trump&#8217;s administration.
&#8220;It takes quite a long time to get a bill through Congress. We have time to make assessments about what the net effects of policy changes will be on the economy before we work with policy,&#8221; he said.
Powell reiterated his concern over the U.S. fiscal trajectory, calling it &#8220;unsustainable.&#8221; 
&#8220;We have a very large deficit at a time when we&#8217;re at full employment,&#8221; Powell said, adding that he and recommended addressing it &#8220;sooner rather than later.&#8221;
When asked about the impact of higher trade tariffs on monetary policy, Powell was cautious but said scenarios involving retaliatory measures from other countries would require close monitoring by the Fed.
<h3 class="wp-block-heading">Market Reactions</h3>
Powell's cautious remarks about the path for interest rates led to a sharp repricing of December rate cut expectations. 
According to the CME FedWatch tool, the probability of a 25-basis-point rate cut in December has dropped, with Fed futures now indicating a 62% chance, down from prior estimates of nearly 80%.
In response, the U.S. dollar rallied, extending its winning streak to five sessions. Treasury yields also reversed course, with significant gains across the curve as investors adjusted their rate expectations. The yield on the two-year Treasury note, which is particularly sensitive to Fed policy shifts, jumped 6 basis points to 4.34%.
Equity markets reacted negatively to Powell's tone. Major U.S. indices turned lower, with the S&amp;P 500, tracked by the SPDR S&amp;P 500 ETF Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>), down 0.7%. The tech-heavy Nasdaq-100, represented by the Invesco QQQ Trust (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QQQ#NASDAQ">QQQ</a>), slipped 0.8%.
Small-cap stocks suffered the most, with the iShares Russell 2000 ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IWM#NYSE">IWM</a>) dropping 1.3%, signaling broader risk aversion among investors. 
<figure class="wp-block-embed is-type-video is-provider-youtube wp-block-embed-youtube wp-embed-aspect-16-9 wp-has-aspect-ratio"> 
<div class="wp-block-embed__wrapper">
<iframe loading="lazy" title="&#x1f534;WATCH LIVE: Dallas Regional Chamber: Global Perspectives with Federal Reserve Chair Jerome Powell" width="500" height="281" src="https://www.youtube.com/embed/vhbdv8jXmvQ?feature=oembed" frameborder="0" allow="accelerometer; autoplay; clipboard-write; encrypted-media; gyroscope; picture-in-picture; web-share" referrerpolicy="strict-origin-when-cross-origin" allowfullscreen></iframe>
</div>
</figure>
Read Next:
<ul>
<li><a href="https://www.benzinga.com/economics/macro-economic-events/24/11/41971830/producer-inflation-rises-more-than-expected-in-october-should-traders-rethink-interest-rate-cut-path">Producer Inflation Rises More Than Expected In October: Should Traders Rethink Interest Rate Cut Path?</a></li>
</ul>
Photo: Jerome Powell at the Nov. 7 FOMC press conference. Photo courtesy of the Federal Reserve.

Broad U.S. Equity ETFs

Econ #s

Economics

Federal Reserve

Markets

ETFs

Powell: With Strong US Economy, Fed Has 'No Need To Be In A Hurry To Lower Rates'

XPON

Expion360 Q3 EPS $(24.55) Up From $(26.25) YoY; Revenue $1.389M Down From $1.890M YoY

DBGI

Digital Brands Group Q3 EPS $(1.63), Sales $2.44M Down From $3.26M YoY

ZURA

Zura Bio Announces Submission Of Protocol To FDA For Phase 2 Study Of Tibulizumab In Adults With Systemic Sclerosis

Offerings

ALPS ETF Trusthen & Steers Global Realty Majors ETF

GRI Bio Files For Offer And Resale By Selling Stockholders Of Up To 1,577,829 Shares Of Common Stock

Q4 2024 Guidance
<ul>
<li>Net Sales are expected to range between $13.5 - $14.0 million</li>
<li>Gross Margin is expected to be in the range of 22.0% - 25.0%</li>
<li>Operating Expenses are expected to be in a range of $(5.5) - $(6.5) million</li>
</ul>

Guidance

DFLI

Dragonfly Energy Sees Q4 2024 Net Sales $13.5M-$14M

CTRI

13F Shows Carl Icahn Added Stake In Centuri Holdings With 1,000,000 Shares

The company has entered into a securities purchase agreement with certain new and existing institutional investors for the purchase of an aggregate of&nbsp;17.50 million common shares of the Company, without par value, and accompanying Class B warrants to purchase up to an aggregate of 8.75 million Common Shares in a registered direct offering.&nbsp;

The Metals Company Plans $17.5M Direct Offering Of Common Shares And Class B Warrants

Vivos Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VVOS#NASDAQ">VVOS</a>) reported quarterly losses of $(0.40) per share which beat the analyst consensus estimate of $(0.79) by 49.37 percent. The company reported quarterly sales of $3.860 million which missed the analyst consensus estimate of $4.061 million by 4.95 percent. This is a 16.93 percent increase over sales of $3.301 million the same period last year.

VVOS

Vivos Therapeutics Q3 2024 GAAP EPS $(0.40) Beats $(0.79) Estimate, Sales $3.860M Miss $4.061M Estimate

OMNIQ (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OMQS#NASDAQ">OMQS</a>) reported quarterly losses of $(0.15) per share. This is a 72.73 percent increase over losses of $(0.55) per share from the same period last year. The company reported $18.55 million in sales this quarter. This is a 7.57 percent increase over sales of $17.24 million the same period last year.

OMQS

OMNIQ Q3 EPS $(0.15) Up From $(0.55) YoY, Sales $18.55M Up From $17.24M YoY

How The U.S. Election Could Impact The Energy Transition

Resilient U.S. Retail Sales Suggests Fed Decision Will Be A Coin Toss

DoE awards $3B for 25 projects to boost U.S. battery production

Winding Road Ahead For China's EV Growth

Can Remarkable U.S. Industrial Revenues Continue?

Harris Or Trump? How The Next President Could Change The Game For Stocks, Taxes, And Inflation

EU tariffs on Chinese EVs go into effect, negotiations with Beijing to continue

Amid The Noise: Four U.S. Value Equity Themes To Monitor

As Markets Sit Near Record Highs, Does This Rally Still Have Room To Run?

Brad Simpson On The Election, Economy, And Why Markets Are Ready To Get 'Back To Business'

Comments

KraneShares Electric Vehicles and Future Mobility Index ETF

Actualités

Dernières nouvelles pour KraneShares Electric Vehicles and Future Mobility Index ETF (ARCA:KARS)

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL